Improving T-cell therapy for solid tumors using a new pre-treatment
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11101299
This work explores a new way to prepare the body for T-cell therapies, hoping to make them more effective against solid tumors like melanoma and neuroblastoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11101299 on ClinicalTrials.gov |
What this research studies
T-cell therapies, like CAR T cells, have shown great success in blood cancers but struggle with solid tumors because the T cells often can't reach or survive well within the tumor. Currently, chemotherapy is used to clear out some immune cells before T-cell therapy, but this can have harsh side effects. This project is testing a new targeted treatment, 67Cu-LLP2A, which aims to more precisely reduce certain immune cells that block T-cell therapies. By combining this targeted treatment with a lower dose of standard chemotherapy, the goal is to help the therapeutic T cells work better against solid tumors with fewer side effects.
Who could benefit from this research
Good fit: Patients with solid tumors, such as melanoma or neuroblastoma, who are candidates for T-cell based immunotherapies may eventually benefit from this research.
Not a fit: Patients with conditions not related to solid tumors or those who are not candidates for T-cell therapy may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer T-cell therapies for patients with solid tumors, potentially improving treatment outcomes.
How similar studies have performed: Adoptive T-cell therapies have shown success in blood cancers, but this specific preconditioning strategy for solid tumors is a novel approach being tested.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PATEL, RAVI BHASKER — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: PATEL, RAVI BHASKER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.